AIP
ELTX icon

Ameritas Investment Partners’s Elicio Therapeutics ELTX Stock Holding History

Ameritas Investment Partners’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-167
Closed -$4K – 3114
2022
Q1 		$4K Hold
167
– – ﹤0.01% 2991
2021
Q4 		$5K Hold
167
– – ﹤0.01% 3036
2021
Q3 		$16K Buy
167
+120
+255% +$13K ﹤0.01% 2800
2021
Q2 		$6K Hold
47
– – ﹤0.01% 2984
2021
Q1 		$9K Buy
+47
New +$9.07K ﹤0.01% 2889

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ameritas Investment Partners's ELTX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 167 shares — an estimated $4K sold.

Ameritas Investment Partners first reported a position in ELTX in Q1 2021 and held it in 5 quarters. The position peaked at $16K in Q3 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 167 Elicio Therapeutics shares in Q2 2022, an estimated $4K.
  • Ameritas Investment Partners first reported a position in Elicio Therapeutics in Q1 2021 and held it in 5 quarters.
  • Ameritas Investment Partners's Elicio Therapeutics position peaked at $16K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.